Generic drugs must meet the same safety, quality, and strength standards as brand-name drugs. The FDA requires identical active ingredients, bioequivalence testing, and strict manufacturing controls. Over 90% of U.S. prescriptions are generics, saving $373 billion annually.
Clinicians are raising alarms about generic drug quality, especially when manufactured overseas. Studies show higher adverse event rates for generics made in India compared to U.S.-made versions. Transparency, inspection reform, and domestic production may be key to fixing the system.